Clinical Trial Update: Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the combination of STI571 (imatinib) and pegylated interferon alfa-2b (PegIntron) for chronic myeloid leukemia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• PegIntron (pegylated interferon alfa-2b)
• STI571 (imatinib)

Snippet

Sponsor: University of Bologna | Conditions: Chronic Myeloid Leukemia | Phase 2 | Status: TERMINATED